ZYME | Zymeworks Inc. Stock Overview

(Stock Exchange: NYSE)

Day's Range	13.85 - 14.35
52 Week Range	7.97 - 17.70
Beta	1.16
Implied Volatility	275.41%
IV Rank	20.27%
Day's Volume	208,964
Average Volume	512,390
Shares Outstanding	68,877,500
Market Cap	973,927,850
Sector	Healthcare
Industry	Biotechnology
IPO Date	2017-04-28

Valuation
Profitability
Growth
Health
P/E Ratio	-9.49
Forward P/E Ratio	N/A
EPS	-1.49
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	294
Country	Canada
Website	ZYME

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.

ZYME's peers: DAWN, INZY, ZNTL, SNDX, PTGX, RVMD, BPMC, STOK, CYTK, RLAY, PRQR, ANNX, ARWR, TERN, AKRO, EDIT, APLS, CABA, ALEC, BLUE, MRSN, YMAB, TVTX

*Chart delayed

Analyzing fundamentals for ZYME we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see ZYME Fundamentals page.

Watching at ZYME technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on ZYME Technicals page.